ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C
Generics BulletinJust ahead of Alvotech publishing its annual results, the biosimilars developer has revealed a first filing for its AVT23 proposed biosimilar to Xolair (omalizumab). In conjunction with partner Advanz
Generics BulletinAlvotech has struck a deal worth SEK275m ($27.0m) to acquire Xbrane BioPharma’s R&D operations in Sweden – based in Campus Solna, at the Karolinska Institute outside Stockholm – as well as the fir
Generics BulletinAlvotech’s AVT03 proposed biosimilar to Prolia/Xgeva (denosumab) has been successfully filed by its partner Dr Reddy’s Laboratories with the US Food and Drug Administration, in the latest development